^
    Back
    Association details:
    Biomarker:PRMT1 underexpression
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oncol Lett
    Title:

    PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma

    Published date:
    12/31/2020
    Excerpt:
    The present study investigated the association between PRMT1 expression and sensitivity to platinum-based chemotherapy in 51 patients with ovarian serous carcinoma...low PRMT1 expression group were more sensitive to platinum-based chemotherapy than those in the high PRMT1 expression group (P=0.01).
    DOI:
    10.3892/ol.2020.12423